Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Bex

Showing results (31-40 of 57) with videos related to

Pageof 6
Sort By:
The Journal of Urology|June 11, 2005
Neoadjuvant methotrexate, vinblastine, doxorubicin and cisplatin for histologically proven lymph node positive bladder cancerJ A Nieuwenhuijzen, A Bex, W Meinhardt, et al.
World Journal of Urology|March 5, 2020
Cytoreductive nephrectomy in metastatic renal cell carcinoma: outcome of patients treated with a multidisciplinary, algorithm-driven approachWing K Liu, J M Lam, T Butters, et al.
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|January 28, 2014
Follow-up after cystectomy: regularly scheduled, risk adjusted, or symptom guided? Patterns of recurrence, relapse presentation, and survival after cystectomyJ A Nieuwenhuijzen, R R de Vries, H van Tinteren, et al.
Cardiovascular and Interventional Radiology|February 14, 2020
Percutaneous Microwave Ablation of Histologically Proven T1 Renal Cell CarcinomaB M Aarts, W Prevoo, M A J Meier, et al.
World Journal of Urology|April 9, 2016
Potentially curable recurrent disease after surgically managed non-metastatic renal cell carcinoma in low-, intermediate- and high-risk patientsY A M Kuijpers, R P Meijer, G N Jonges, et al.
Cancer Immunology, Immunotherapy : CII|May 21, 2005
Prolonged low dose IL-2 and thalidomide in progressive metastatic renal cell carcinoma with concurrent radiotherapy to bone and/or soft tissue metastasis: a phase II studyJ M Kerst, A Bex, H Mallo, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 28, 2010
Outcome of treatment discontinuation in patients with metastatic renal cell carcinoma and no evidence of disease following targeted therapy with or without metastasectomyM Johannsen, M Staehler, C-H Ohlmann, et al.
The Prostate|November 14, 2000
Novel amplification unit at chromosome 3q25-q27 in human prostate cancerH P Sattler, R Lensch, V Rohde, et al.
Urologia Internationalis|March 22, 2012
Short-term outcome after cystectomy: comparison of two different perioperative protocolsR R de Vries, P Kauer, H van Tinteren, et al.
World Journal of Urology|August 10, 2012
Differences in histopathological evaluation of standard lymph node dissections result in differences in nodal count but not in survivalL S Mertens, R P Meijer, E van Werkhoven, et al.
Pageof 6

Showing results (31-40 of 57) with videos related to

Sort By:
Pageof 6
The Journal of Urology|June 11, 2005
Neoadjuvant methotrexate, vinblastine, doxorubicin and cisplatin for histologically proven lymph node positive bladder cancerJ A Nieuwenhuijzen, A Bex, W Meinhardt, et al.
World Journal of Urology|March 5, 2020
Cytoreductive nephrectomy in metastatic renal cell carcinoma: outcome of patients treated with a multidisciplinary, algorithm-driven approachWing K Liu, J M Lam, T Butters, et al.
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|January 28, 2014
Follow-up after cystectomy: regularly scheduled, risk adjusted, or symptom guided? Patterns of recurrence, relapse presentation, and survival after cystectomyJ A Nieuwenhuijzen, R R de Vries, H van Tinteren, et al.
Cardiovascular and Interventional Radiology|February 14, 2020
Percutaneous Microwave Ablation of Histologically Proven T1 Renal Cell CarcinomaB M Aarts, W Prevoo, M A J Meier, et al.
World Journal of Urology|April 9, 2016
Potentially curable recurrent disease after surgically managed non-metastatic renal cell carcinoma in low-, intermediate- and high-risk patientsY A M Kuijpers, R P Meijer, G N Jonges, et al.
Cancer Immunology, Immunotherapy : CII|May 21, 2005
Prolonged low dose IL-2 and thalidomide in progressive metastatic renal cell carcinoma with concurrent radiotherapy to bone and/or soft tissue metastasis: a phase II studyJ M Kerst, A Bex, H Mallo, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 28, 2010
Outcome of treatment discontinuation in patients with metastatic renal cell carcinoma and no evidence of disease following targeted therapy with or without metastasectomyM Johannsen, M Staehler, C-H Ohlmann, et al.
The Prostate|November 14, 2000
Novel amplification unit at chromosome 3q25-q27 in human prostate cancerH P Sattler, R Lensch, V Rohde, et al.
Urologia Internationalis|March 22, 2012
Short-term outcome after cystectomy: comparison of two different perioperative protocolsR R de Vries, P Kauer, H van Tinteren, et al.
World Journal of Urology|August 10, 2012
Differences in histopathological evaluation of standard lymph node dissections result in differences in nodal count but not in survivalL S Mertens, R P Meijer, E van Werkhoven, et al.
Pageof 6